A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the
percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with
levodopa.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.